Tristel Regulatory News (TSTL)

Tristel plc

("Tristel" or the "Company")

AGM Statement and notice of results

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, will hold its Annual General Meeting at 11am today at Lynx Business Park, Fordham Road, Newmarket, Cambridgeshire CB8 7NY.

Paul Swinney, Chief Executive Officer, will address the meeting with the following update:

"The Company is returning to its pre-pandemic growth trajectory, with first half revenue expected to exceed £17m, compared to £15m in the first half of last year. Revenue growth is consistent across all our geographical markets. Gross margin is in line with expectations.

"With respect to North America, we have made our first sales in the United States and Canada, and we are preparing the additional data requested by the FDA in September. We expect to submit it in March next year, meeting the FDA's deadline and facilitating a decision from the agency around our year-end in June. We remain confident of a successful outcome.

"The Company is making good progress. With no debt and cash of approximately £10m we face the prevailing economic environment with confidence."

Notice of Results

The Company's unaudited interim results will be announced on 20 February 2023.

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

For further information please contact: